Notas de prensa
- Industria biofarmacéutica
- General
STA Pharmaceutical to open new transition metal catalysis center in Changzhou, China
The center will allow STA to introduce transition metal catalyst-screening technology to their existing small molecule process development and manufacturing platform.
STA Pharmaceutical, a WuXi AppTec company, has announced plans to launch a new transition metal catalysis center at their integrated API process R&D and manufacturing site in Changzhou China. The new state-of-the-art facility will allow STA to carry out rapid screening of metal catalysts, ligands, bases, acids, chemical resolving reagents, and amide formation coupling reagents, etc. The screening kits will enable high-throughput screening of metal catalysts and ligands for C-C, C-N, C-O and C-S formation reactions, as well as many other types of reactions such as chemical resolution and amide formation. The technology allows the STA team to more rapidly find the optimal catalysts using a parallel interactive testing approach.
A team of scientists specialized in this technology are currently being trained in the company’s Shanghai R&D center, and, once the new center becomes fully operational in early November, will move to the Changzhou site.
Media Contacts // De Facto Communications:
Alex Heeley or Alex Allsop
T: +44 (0) 203 735 8168
E: a.heeley@defacto.com / a.allsop@defacto.com
